Claris Ventures SGR SpA
Claris Ventures SGR SpA is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Claris Ventures SGR SpA.
Claris Ventures SGR SpA is a company.
Key people at Claris Ventures SGR SpA.
Key people at Claris Ventures SGR SpA.
Claris Ventures SGR SpA is an Italian venture capital firm based in Turin, specializing in equity investments in early-stage biopharma and life sciences companies with strong scientific foundations.[1][2][5] Its mission centers on supporting biotech startups from the Italian research ecosystem, focusing on therapeutic areas like oncology, neurology, cardiometabolic diseases, and rare diseases, to drive clinical validation and eventual partnerships or M&A with pharmaceutical giants.[3] The investment philosophy emphasizes selective bets on programs addressing unmet clinical needs with high potential impact.[1][3] Key sectors include biotechnology and healthcare innovation.[4][5] Through funds like Claris Biotech I (€85 million, backing 10 companies) and Claris Biotech II (€100 million target), the firm bolsters Italy's startup ecosystem by bridging academic research to commercial viability, attracting institutional backers like CDP Venture Capital and the European Investment Fund.[3]
Founded in 2019 in Torino, Italy, Claris Ventures emerged as a dedicated player in the life sciences venture space.[5] Key partners include Managing Partner Ciro Spedaliere, Partner Michael Hodges, Manager Laura Iris Ferro, and Advisor Luca Melindo, who lead its operations.[5] The firm's evolution kicked off with Claris Biotech I in 2020, raising €85 million by July 2021 to finance 10 early-stage biotech firms, proving its scouting prowess and value creation in a nascent Italian biotech scene.[3][5] This success paved the way for Claris Biotech II, announced with a first closing in April 2025, maintaining a sharp focus on high-potential drug development programs from local research hubs.[3]
Claris Ventures rides the wave of Europe's biotech resurgence, fueled by post-pandemic R&D investments and Italy's strengthening research output in drug discovery.[3] Timing is ideal amid rising demand for innovative therapies in oncology and rare diseases, where market forces like aging populations and pharma M&A activity (€ billions in deals annually) favor agile early-stage funders.[3] By channeling public-private capital into Italian-origin startups, it counters brain drain in life sciences, amplifies EIF/CDP priorities for societal impact, and influences the ecosystem through portfolio successes that validate regional innovation hubs.[3]
Claris Ventures is poised to expand its portfolio with Biotech II's full close, potentially financing 10+ more startups amid biotech's funding rebound.[3] Trends like AI-driven drug discovery and cross-border pharma partnerships will shape its path, enhancing deal flow from Italy's universities.[3] Its influence may grow as a model for specialized European VC, drawing more EIF-style mandates and solidifying Turin as a biotech node—echoing its founding bet on evidence-backed innovation to transform patient outcomes.[1][3]
